Johnson & Johnson (JNJ) made headlines with its definitive agreement to acquire Halda Therapeutics, a privately head clinical-stage biotech company famed for its Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, in a $3.05 billion cash deal. The strategic move, set to strengthen…
